Purple Biotech (PPBT) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Purple Biotech announced positive results from its Phase 2 study of CM24 for pancreatic cancer, showing significant improvements in survival rates when combined with nivolumab and chemotherapy. The study highlights its potential as a promising treatment option with a 79% reduction in risk of death in certain biomarker-enriched patient groups. Investors may find these results encouraging as the company moves forward with plans for further clinical studies.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
